These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 11913472)

  • 41. [Myocardial cytoprotection with trimetazidine in patients with ischemic heart disease during surgical stress].
    Afanas'eva IV; Goncharova LL; Miroshnichenko AG; Petrash VV; Pokrovskaia LA
    Vestn Khir Im I I Grek; 1999; 158(5):34-7. PubMed ID: 10645577
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Coronary-ventricular sinusoid communications].
    Aispuru GR; Ugartemendia M; Páez Gill NE; Grimolizzi NS; Caminiti N
    Medicina (B Aires); 2009; 69(5):562. PubMed ID: 19897445
    [No Abstract]   [Full Text] [Related]  

  • 43. Trimetazidine and cardioprotection: facts and perspectives.
    Tsioufis K; Andrikopoulos G; Manolis A
    Angiology; 2015 Mar; 66(3):204-10. PubMed ID: 24719262
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Trimetazidine in Practice: Review of the Clinical and Experimental Evidence.
    Dézsi CA
    Am J Ther; 2016; 23(3):e871-9. PubMed ID: 25756467
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Trimetazidine to reverse ischemia in patients with class I or II angina: a randomized, double-blind, placebo-controlled dobutamine-atropine stress echocardiography study.
    Cesar LA; Mathias W; Armaganijan D; Gimenez V; Jallad S; Del Monaco MI; Bicudo L; Meneguin S; Gomes EP; Brasil CK; Ramires JF
    Coron Artery Dis; 2007 Jun; 18(4):259-63. PubMed ID: 17496489
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effect of partial inhibition of fatty acid oxidation by trimetazidine on whole body energy metabolism in patients with chronic heart failure.
    Fragasso G; Salerno A; Lattuada G; Cuko A; Calori G; Scollo A; Ragogna F; Arioli F; Bassanelli G; Spoladore R; Luzi L; Margonato A; Perseghin G
    Heart; 2011 Sep; 97(18):1495-500. PubMed ID: 21700755
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effects of trimetazidine in nonischemic heart failure: a randomized study.
    Winter JL; Castro PF; Quintana JC; Altamirano R; Enriquez A; Verdejo HE; Jalil JE; Mellado R; Concepción R; Sepúlveda P; Rossel V; Sepúlveda L; Chiong M; García L; Lavandero S
    J Card Fail; 2014 Mar; 20(3):149-54. PubMed ID: 24412523
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Metabolic modulators for chronic cardiac ischemia.
    Parang P; Singh B; Arora R
    J Cardiovasc Pharmacol Ther; 2005 Dec; 10(4):217-23. PubMed ID: 16382258
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The metabolic approach in patients with heart failure: effects on left ventricle remodeling.
    Tang WH
    Curr Pharm Des; 2009; 15(8):850-6. PubMed ID: 19275649
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Metabolic therapy for heart failure].
    Loiacono F; Alberti L; Lauretta L; Puccetti P; Silipigni C; Margonato A; Fragasso G
    Recenti Prog Med; 2014; 105(7-8):288-94. PubMed ID: 25072544
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Therapeutic application of myocardial cytoprotection].
    Ribeiro C
    Rev Port Cardiol; 1994 Sep; 13(9):669-70. PubMed ID: 7818940
    [No Abstract]   [Full Text] [Related]  

  • 52. [The use of metabolic therapy in the treatment of ischemic heart disease in hemodynamically formed insignificant aortic stenosis with chronic heart failure].
    Kuriata AV; Karavanskaia IL; Kushnir IuS
    Lik Sprava; 2011; (7-8):51-8. PubMed ID: 22768738
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prognostic relevance of metabolic approach in patients with heart failure.
    Di Napoli P; Barsotti A
    Curr Pharm Des; 2009; 15(8):883-92. PubMed ID: 19275652
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Energy substrate metabolism, myocardial ischemia, and targets for pharmacotherapy.
    Taegtmeyer H; King LM; Jones BE
    Am J Cardiol; 1998 Sep; 82(5A):54K-60K. PubMed ID: 9737487
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Trimetazidine improves left ventricular function and quality of life in elderly patients with coronary artery disease.
    Vitale C; Wajngaten M; Sposato B; Gebara O; Rossini P; Fini M; Volterrani M; Rosano GM
    Eur Heart J; 2004 Oct; 25(20):1814-21. PubMed ID: 15474696
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effects of trimetazidine on the contractile response of chronically dysfunctional myocardium to low-dose dobutamine in ischaemic cardiomyopathy.
    Belardinelli R; Purcaro A
    Eur Heart J; 2001 Dec; 22(23):2164-70. PubMed ID: 11913478
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Influence of trimetazidine and ranolazine on endothelial function in patients with ischemic heart disease.
    Rehberger-Likozar A; Šebeštjen M
    Coron Artery Dis; 2015 Dec; 26(8):651-6. PubMed ID: 26049922
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Anti-ischemic effects of trimetazidine in patients with post-infarction heart failure].
    Tepliakov AT; Sankevich qV; Stepacheva TA; Garganeeva AA; Filippov EA; Pushnikova EIu; Kaliuzhin VV; Efimova I; Zavadovskiĭ KV
    Klin Med (Mosk); 2004; 82(5):57-62. PubMed ID: 15230045
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Mechanisms of myocardial cell protection from ischemia/reperfusion injury and potential clinical implications].
    Lamendola P; Di Monaco A; Barone L; Pisanello C; Lanza GA; Crea F
    G Ital Cardiol (Rome); 2009 Jan; 10(1):28-36. PubMed ID: 19292017
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [A clinical experience of taurine and trimetazidine use in premenopausal women with chronic heart failure].
    Sedova EM; Magnitskaia OV
    Kardiologiia; 2010; 50(1):62-3. PubMed ID: 20144159
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.